RYTM did a 120% run in November and December and then pivoted to start the year. It competes
in the anti-obesity drug space which is all the rage right now and has snack food manufactures
freaking out. The retrace was a shallow one in a sign of strength finding support at the 0.382
retracement level and then pivoting into a reversal in the past week. The dual...
NASDAQ:RYTM This stock seems to be following a textbook Wyckoff market cycle and appears to be transitioning from markup to markdown.
Mid May was the beginning of a multi week base building/accumulation On June 16-17 we can see the "spring" that preceded a huge markup in prices. After that a sharp rally in prices into the $11-$13 range that formed a...
"Do you see what I see?
Way up in the sky, little lamb
Do you see what I see?
A star, a star, dancing in the night
With a tail as big as a kite
With a tail as big as a kite"
This shows the bullish setup for RYTM according to the Bounce 2.0 criteria (from Tao of Trading), on 9/9/2022. It does not yet consider the entry trigger.
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase...
RYTM releases phase 3 trial data for their drug, Setmelanotide , on the 20th. Also, their chart looks very bullish. They recently broke out of their downtrend, which as you can see from the past is an extremely bullish sign. They also appear to be at the bottom of their current channel. Another bullish sign is the low volume. This means that good news could make...
$RYTM - the stock has approached the lower boundary of the uptrend starting on 3/16/20. Support levels other than the trend line are:
- two VWAP lines: 1st from the minimum value (3/16/20) and 2nd from the IPO date.
- 200D EMA
- Support zone, which has already been repeatedly tested.
MACD indicator is in the negative zone and has crossed the signal...
RYTM: Rhythm Pharmaceuticals, Inc.
2020-11-27 07:30:00
Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE™ (setmelanotide) as First-ever Therapy for Chronic Weight Management in Patients with Obesity Due to POMC, PCSK1 or LEPR Deficiency
